As infections caused by methicillin-resistant Staphylococcus aureus are gaining attention for causing more than 19,000 deaths per year in the U.S., Biotech firm Cepheid has found success with the rapid adoption of its genetic test designed to help hospitals quickly detect MRSA. "We're in the right place at the right time with the right technology," the company's chief medical officer said.

Related Summaries